Ptc Therapeutics (PTCT) analyst forecast and price target
Analyst forecast
Consensus of 15 analyst ratings
Based on 6 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $122.00 from $120.00 | Aug 14, 2026 |
| Wells Fargo | Maintained | Overweight | $109.00 from $106.00 | Aug 13, 2026 |
| Wells Fargo | Maintained | Overweight | $106.00 from $93.00 | Jul 31, 2026 |
| Morgan Stanley | Maintained | Overweight | $104.00 from $93.00 | Jul 31, 2026 |
| Wells Fargo | Maintained | Overweight | $93.00 from $95.00 | Jul 20, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $130.00 from $124.00 | Jul 16, 2026 |
| RBC Capital | Maintained | Sector Perform | $85.00 from $82.00 | Jul 7, 2026 |
| Citigroup | Initiated Coverage | Neutral → Buy | $108.00 from $75.00 | Jun 9, 2026 |
| Jefferies | Upgraded | Hold → Buy | $85.00 from $76.00 | May 27, 2026 |
| Wells Fargo | Maintained | Overweight | $95.00 from $86.00 | May 8, 2026 |
| RBC Capital | Maintained | Sector Perform | $82.00 from $81.00 | May 8, 2026 |
| TD Cowen | Upgraded | Hold → Buy | $90.00 from $75.00 | May 8, 2026 |
| Jefferies | Downgraded | Buy → Hold | $76.00 from $91.00 | Mar 30, 2026 |
| Morgan Stanley | Maintained | Overweight | $92.00 from $90.00 | Feb 23, 2026 |
| B of A Securities | Maintained | Buy | $93.00 from $97.00 | Feb 20, 2026 |
| RBC Capital | Maintained | Sector Perform | $82.00 from $87.00 | Feb 20, 2026 |
| Wells Fargo | Maintained | Overweight | $86.00 from $93.00 | Feb 20, 2026 |
| Barclays | Upgraded | Equal-Weight → Overweight | $119.00 from $68.00 | Jan 28, 2026 |
| RBC Capital | Downgraded | Outperform → Sector Perform | $91.00 from $82.00 | Dec 1, 2025 |
| Barclays | Maintained | Equal-Weight | $68.00 from $46.00 | Nov 6, 2025 |
Frequently asked questions
What is the price target for PTCT stock?
The average 12-month analyst price target for Ptc Therapeutics (PTCT) is $109.67, with a high estimate of $130.00 and a low of $85.00, across 6 analysts.
Is PTCT a buy, sell, or hold?
Analysts covering Ptc Therapeutics currently average a Buy rating: 11 buy, 3 hold and 1 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for PTCT?
The average price target of $109.67 implies 59.05% upside from the last price of $68.95.
What is the latest analyst rating on PTCT?
On Aug 14, 2026, Barclays maintained Ptc Therapeutics at Overweight with a price target of $122.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.